세계의 포스포로아미다이트 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Phosphoramidite Market was valued at USD 1.2 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 2.4 billion by 2034. This market growth is driven by the rising demand for oligonucleotides used in diagnostics, gene therapy, and drug development. The increasing focus on genetic research and gene editing, alongside the growing application of phosphoramidite for the synthesis of oligonucleotides, has contributed significantly to the market's expansion. Additionally, advancements in therapeutic methods such as CRISPR-Cas9 and other molecular biology technologies have spurred the demand for synthetic phosphoramidites. The global focus on molecular biology research, genome sequencing, and synthetic biology further fuels the growth of this market, especially with the rising prevalence of genetic disorders, infectious diseases, and cancers.

Targeted therapies that require the synthesis of oligonucleotides are becoming more common, thus driving the need for phosphoramidites. These therapies, which are designed to target specific genetic mutations or disease-causing genes, rely heavily on precise and efficient synthesis of oligonucleotides for their effectiveness. As advancements in gene therapies, personalized medicine, and genomic research continue to grow, the demand for high-quality phosphoramidites has surged. Phosphoramidites play a crucial role in enabling the creation of custom DNA and RNA sequences for use in these innovative treatments, thus fueling their growing market. The expanding applications of oligonucleotides in cancer treatment, genetic disorders, and infectious diseases further contribute to the increased need for phosphoramidites.

The demand for the DNA phosphoramidites segment remains robust valued at USD 642.8 million in 2024. As these phosphoramidites are essential for the synthesis of both DNA and RNA sequences, their use has expanded in fields such as gene therapy and molecular diagnostics. The production of high-quality phosphoramidites has become more efficient due to advancements in synthesis technologies, purification methods, and automation, making DNA phosphoramidites more accessible and cost-effective. As biotechnology companies increasingly outsource the large-scale production of oligonucleotides, this segment continues to see significant growth.

The drug discovery and development segment accounted for a 38.7% share in 2024. This is largely driven by the growing focus on DNA and RNA-based therapies that require precise oligonucleotide synthesis. The rising need for innovative therapies for various chronic diseases, along with advances in early diagnostic methods like PCR, further stimulates the market for phosphoramidite. The increasing demand for accuracy in diagnosing genetic and infectious disorders is contributing to this growth. In addition, ongoing improvements in screening methods are accelerating drug development and optimizing the use of phosphoramidite in the process.

U.S. Phosphoramidite Market was valued at USD 487.9 million in 2024, with the growing demand for oligonucleotide-based therapies for molecular diagnostics and gene therapies driving the market. Investments in genetic research, including gene therapy advancements, have led to a rise in funding and infrastructure in the U.S., further fueling the market. In addition, the need for high-quality reagents and solutions for the synthesis of DNA and RNA-based therapies, as well as next-generation sequencing, is expected to drive the demand for phosphoramidites in the U.S. The market is also benefiting from favorable government initiatives and the presence of leading industry players.

Key players in the Global Phosphoramidite Market include Bioneer, PolyOrg, Biosynth, BOC Sciences, ChemGenes, Sigma-Aldrich (Merck KGaA), Creative Biolabs, Danaher, Glen Research, Hongene Biotech, LGC Biosearch Technologies, Lumiprobe, Qiagen, Thermo Fisher Scientific, and TriLink Bio Technologies. Companies in the phosphoramidite market strengthen their position by investing in research & development, especially in the fields of gene therapy and diagnostic applications. They focus on advancing synthesis technologies and improving the efficiency of production processes to reduce costs and enhance the scalability of DNA and RNA-based therapies. Many companies are forming strategic partnerships with biotechnology firms to enhance their product offerings and extend their market reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Type
  • 2.2.3 Application
  • 2.2.4 End use
• 2.3 CXO perspectives: strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for genetic research and biotechnology
    • 3.2.1.2 Rising prevalence of RNA-based therapeutics
    • 3.2.1.3 Technological advancements in diagnostic techniques
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Complexity in synthesis and purity standards
    • 3.2.2.2 Limited market awareness and infrastructure in emerging markets
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising demand for high-throughput and automated oligo synthesis
    • 3.2.3.2 Rise in government and defense genomics initiatives
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 DNA phosphoramidites
• 5.3 RNA phosphoramidites
• 5.4 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery and development
• 6.3 Diagnostics
• 6.4 Personalized medicine
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Academic and research institutes
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Bioneer
• 9.2 Biosynth
• 9.3 BOC Sciences
• 9.4 ChemGenes
• 9.5 Creative Biolabs
• 9.6 Danaher
• 9.7 Glen Research
• 9.8 Hongene Biotech
• 9.9 LGC Biosearch Technologies
• 9.10 Lumiprobe
• 9.11 PolyOrg
• 9.12 Sigma-Aldrich (Merck KGaA)
• 9.13 Qiagen
• 9.14 Thermo Fisher Scientific
• 9.15 TriLink Bio Technologies